-
"Peroxin" withdrew from the Chinese market; The growth of the "troika" is weak; How does Roche continue to shine?
Time of Update: 2022-10-12
196 billion; at present, only Roche Pharmaceutical Pailuoxin and Tebao Bio Hepatitis B infectious hormone Paigebin, two polyethylene glycol interferon α-2b injections are listed, it is worth noting that before Pailokhin was Roche's champion product in China - interferon brand sales champion, and repeatedly exchanged price for volume, prompting its rapid growth in the Chinese market.
-
The ophthalmic treatment track has begun, and domestic and foreign pharmaceutical companies are competing for layout
Time of Update: 2022-10-12
【Pharmaceutical Network Industry News】With the intensification of population aging and the increase in the use of electronic products, age-related eye diseases, metabolism-related eye diseases and fun
-
Announcement of the State Food and Drug Administration on the Issuance of Electronic Registration Certificates for Drugs (No. 83 of 2022)
Time of Update: 2022-10-12
Today, the State Food and Drug Administration issued an announcement on the issuance of electronic registration certificates for drugs (No. 83 of 2022), the details of which are as follows: In order
-
Notice of the Drug Review Center of the State Food and Drug Administration on the Issuance of the Technical Guidelines for the Research of Clinical Dependence of Drugs (Trial) (No. 35 [2022])
Time of Update: 2022-10-12
Notice of the Drug Review Center of the State Food and Drug Administration on the Issuance of the Technical Guidelines for the Research of Clinical Dependence of Drugs (Trial) (No. 35 [2022]) Release date: 20220928 Drug clinical dependence research is an important research content before the market of new drugs with potential abuse risks, and there is no specialized technical requirement for standardized management of such studies in China.
-
Notice on the Public Solicitation of Opinions on the Technical Guidelines for the Preparation and Research of Drugs for Clinical Trial Use of New Chinese Medicines (Draft for Solicitation of Comments).
Time of Update: 2022-10-12
Release date: 20220927 In order to accelerate the establishment and improvement of a technical evaluation system that meets the characteristics of traditional Chinese medicines and promote the research and development and innovation of new drugs based on traditional Chinese medicines in China, the Drug Review Center has drafted the "Technical Guidelines for the Preparation and Research of Drugs for Clinical Trial of New Drugs in Traditional Chinese Medicines".
-
Another multinational pharmaceutical company sold its factories in China to rearrange its business in the Chinese market
Time of Update: 2022-10-12
【Pharmaceutical Network Industry Dynamics】 In recent years, multinational pharmaceutical companies are generally facing the "patent cliff" of original research drugs, and in this context, multinational pharmaceutical companies have also become very frequent in selling business in China.
-
The domestic demand for medicinal glass tubes is increasing, and the pharmaceutical glass faucet is accelerating the expansion of production
Time of Update: 2022-10-12
【Pharmaceutical Network Industry News】In recent years, with the continuous expansion of the pharmaceutical market and the stricter supervision of the industry, the quality and safety of drugs have att
-
In October, a batch of drugs were evaluated, and some varieties won the first home!
Time of Update: 2022-10-12
Enhua Pharmaceutical announced at noon on October 10 that the company's flumazenil injection recently passed the consistency evaluation of generic drug quality and efficacy.
Enhua Pharmaceutical announced at noon on October 10 that the company's flumazenil injection recently passed the consistency evaluation of generic drug quality and efficacy.
-
Ashland fully upgrades Viatel™ Smart Bio absorbable materials capacity and R&D capabilities
Time of Update: 2022-10-12
com Scan the code to follow the latest developments in Ashland China Wilmington, Delaware, Aug. 30, 2022 – Ashland announces the expansion of Viatel's™ smart bioabsorbable materials production and R&D facility at the National Science Park in Maringa, Ireland.
-
The official disclosure period of the third quarterly report is coming! The net profit of some pharmaceutical companies increased sharply year-on-year
Time of Update: 2022-10-12
According to the statistics of the lower limit of the net profit attributable to the forecast, 63 stocks achieved a year-on-year increase in net profit, accounting for 70%.
-
The deputy general manager of "Pharmaceutical Brother" is replaced, or accelerate the promotion of research and development
Time of Update: 2022-10-12
It is understood that Tao Weikang, who left the company, has served as deputy general manager of Shanghai Hengrui Pharmaceutical Co.
It is understood that Tao Weikang, who left the company, has served as deputy general manager of Shanghai Hengrui Pharmaceutical Co.
-
Notice on the "Symposium on the Selection and Safety Evaluation of Excipients for Children's Drugs"
Time of Update: 2022-10-12
Notice on the "Symposium on the Selection and Safety Evaluation of Excipients for Children's Drugs" Release date: 20220930 In order to encourage the research and development of children's drugs and e
-
Letter on the Public Solicitation of Opinions on the Guiding Principles for the Naming of Generic Names of Chemical Drugs
Time of Update: 2022-10-12
xlsx In order to do a good job in the naming of generic names of chemical drugs, our committee has organized the drafting of the "Guiding Principles for the Naming of Common Names of Chemical Drugs (Draft for Solicitation of Comments)" (see Annex 1), which is now open to the public for comments.
-
The reform of traditional Chinese medicine medical insurance payment methods has accelerated, and many places have ushered in new breakthroughs
Time of Update: 2022-10-12
In 2021, the Medical Security Bureau of the Autonomous Region launched the pilot project of "Payment Methods Suitable for the Characteristics of Traditional Chinese Medicine under the Comprehensive Reform of Medical Insurance DRG Payment" in Liuzhou, and the reform path mainly includes payment for the dominant diseases of traditional Chinese medicine, payment according to the value of curative effect, and payment according to the diagnosis of Western medicine in the dual diagnosis into the DRG group.
-
In order to break the competition in the same industry, this Chinese medicine tablet company has a new action!
Time of Update: 2022-10-12
【Pharmaceutical Network Industry News】Chinese medicine tablets are one of the three pillars of China's traditional Chinese medicine industry, which is in the middle link of the traditional Chinese med
-
The cooperation between Chinese and foreign pharmaceutical companies has become more frequent, and the content of cooperation has shown a trend of diversification
Time of Update: 2022-10-12
【Pharmaceutical Network Industry News】The cooperation between Chinese and foreign pharmaceutical companies is becoming more and more frequent, and the cooperation content is diversified Recently, the signing ceremony of Merck Group's trademark license and the signing of the biological wisdom valley (Chengdu) Technology Co.
-
Progress in rare disease drug research in China
Time of Update: 2022-10-12
(See Figure 2 for details) Although the economic return is not the most cost-effective, the proportion of rare disease drug research and development in the world's leading pharmaceutical companies is relatively high.
-
A number of local API companies pass Jiayin, which is related to the approval of products and the construction of production capacity
Time of Update: 2022-10-12
Hokuriku Pharmaceutical announced on the evening of September 29 that recently, the company's repaglinide API received the "Notice of Approval of Chemical API Listing Application" issued by the State Food and Drug Administration.
-
Over 18 billion yuan of market, a large number of domestic pharmaceutical companies are actively layout!
Time of Update: 2022-10-12
Recently, there have been reports that the FDA has approved Auvelity, a new drug developed by Axsome, for the treatment of Major Depressive Disorder (MDD) in adults.
-
The commercialization/R&D of innovative drugs is constantly achieving new breakthroughs, and it is recommended to pay attention to these companies
Time of Update: 2022-10-12
【Pharmaceutical Network Industry News】 Biomedical innovation is related to people's health, and the development of pharmaceutical industry is the fundamental embodiment and guarantee of the people's p
